iMEAN
- Founded in: 2018
- Number of employees: -
- Country: France
- Investors: Love money
- Market: Synthetic Biology
- Website: www.imean-biotech.com
Which input provides your business model/core technology towards a bio-based economy?
We provide services for R&D projects of biotechnology companies. We help during the design phase of biosolutions. Our technology, based on virtual organisms, mimics in silico experimental processes. Thus, we accelerate R&D processes by reducing wet phase, we secure R&D output by avoiding dead-end solutions, we drive the R&D processes toward patentable products within bioeconomy.
Which market/clients do you address and which short-term/long-term goals do you have?
In the short term, we propose services to design synthetic organisms for industrial microbiology. We developed our “tracker” AI algorithm and performed a convincing proof of concept in designing methylotrophs organisms.
in the long term, we are developing a prototype of virtual crop selection process for breeding companies. We aim to validate the prototype within 2 years.
What makes your approach unique compared to other stakeholders in the field?
Behavior of our virtual organisms rely on causal mechanisms within complex molecular networks of living cells. Although metabolic network modelling is commonly optimised, we are experts in including and designing regulatory modules.
Our crop virtual selection service is without equivalent in the world by combining quantitative genetics methods with systems biology methods.
You can meet iMEAN in Toulouse at the START-UP VILLAGE @EFIB on 17-18 October.